Luminespib

 ( Carboxamides ) 

Luminespib (INN, previously known as NVP-AUY922) is an experimental drug candidate for the treatment of cancer. It was discovered through a collaboration between The Institute of Cancer Research and the pharmaceutical company Vernalis plc and licensed to Novartis. From 2011 to 2014 it was in Phase II clinical trials. Chemically it is a Resorcinol isoxazole amide

Luminespib is an enzyme inhibitor of heat shock protein 90 (Hsp90), which is a chaperone protein that plays a role in the modification of a variety of proteins that have been implicated in oncogenesis. Luminespib has shown promising activity in preclinical testing against several different tumor types.

A related compound, NVP-HSP990, was abandoned by Novartis in 2012 after it failed to show efficacy in an early clinical trial.

• Hsp90 inhibitors